An integrin-targeted photoactivatable Pt(iv) complex as a selective anticancer pro-drug: Synthesis and photoactivation studies

A new anticancer agent based on the conjugation of a photoactivatable Pt(iv) pro-drug to a cyclic RGD-containing peptide is described. Upon visible light irradiation, phototoxicity was induced preferentially in SK-MEL-28 melanoma cancer cells overexpressing α<inf>V</inf>β<inf>3</inf> integrin compared to control DU-145 human prostate carcinoma cells ​
Aquest document està subjecte a una llicència Creative Commons:Reconeixement (by) Creative Commons by3.0